Recurrent high-grade glioma treated with bevacizumab: prognostic value of MGMT methylation, EGFR status and pretreatment MRI in determining response and survival

Title
Recurrent high-grade glioma treated with bevacizumab: prognostic value of MGMT methylation, EGFR status and pretreatment MRI in determining response and survival
Authors
Keywords
High-grade glioma, Bevacizumab, Anti-angiogenic therapy, MRI biomarkers, Tissue biomarkers
Journal
JOURNAL OF NEURO-ONCOLOGY
Volume 115, Issue 2, Pages 267-276
Publisher
Springer Nature
Online
2013-08-21
DOI
10.1007/s11060-013-1225-0

Ask authors/readers for more resources

Reprint

Contact the author

Find the ideal target journal for your manuscript

Explore over 38,000 international journals covering a vast array of academic fields.

Search

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started